Related references
Note: Only part of the references are listed.First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients
Marion Ort et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2022)
Avacopan for the Treatment of ANCA-Associated Vasculitis
David R. W. Jayne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria
Alexander Roeth et al.
BLOOD (2020)
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
James F. Howard et al.
JAMA NEUROLOGY (2020)
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
Adrianna Latuszek et al.
PLOS ONE (2020)
Circadian Clock and Complement Immune System-Complementary Control of Physiology and Pathology?
Pooja Shivshankar et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway
Marion Ort et al.
FRONTIERS IN IMMUNOLOGY (2020)
Sex differences in the inflammatory response to stress and risk of adverse cardiovascular outcomes among patients with coronary heart disease
Samaah Sullivan et al.
BRAIN BEHAVIOR AND IMMUNITY (2020)
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis
Gerard Socie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Compendium of current complement therapeutics
Wioleta M. Zelek et al.
MOLECULAR IMMUNOLOGY (2019)
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
Niels C. Riedemann et al.
CLINICAL IMMUNOLOGY (2017)
Complement in disease: a defence system turning offensive
Daniel Ricklin et al.
NATURE REVIEWS NEPHROLOGY (2016)
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
Pirow Bekker et al.
PLOS ONE (2016)
Complement, a target for therapy in inflammatory and degenerative diseases
B. Paul Morgan et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade
Jennifer Vandooren et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Jun Yuan et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Sleep and circadian rhythm regulate circulating complement factors and immunoregulatory properties of C5a
Edimara S. Reis et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
Inhibiting the C5-C5a receptor axis
Trent M. Woodruff et al.
MOLECULAR IMMUNOLOGY (2011)
Complement: a key system for immune surveillance and homeostasis
Daniel Ricklin et al.
NATURE IMMUNOLOGY (2010)
Complement component 5a (C5a)
Helga D. Manthey et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Function, structure and therapeutic potential of complement C5a receptors
P. N. Monk et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils
Richard G. DiScipio et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Share Paper
